Cargando…

Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors

Detalles Bibliográficos
Autores principales:	Cavazzoni, Andrea, Palladini, Arianna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086415/ https://www.ncbi.nlm.nih.gov/pubmed/37056348 http://dx.doi.org/10.3389/fonc.2023.1180650

Ejemplares similares

Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy — non-mitotic mechanisms of paclitaxel
por: Smith, Elizabeth R., et al.
Publicado: (2022)

Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
por: Digiacomo, Graziana, et al.
Publicado: (2020)

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
por: Digiacomo, Graziana, et al.
Publicado: (2022)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
por: Schettini, Francesco, et al.
Publicado: (2018)

Editorial: Novel Combination Therapies for the Treatment of Solid Cancers
por: Ayoub, Nehad M.
Publicado: (2021)

CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
por: Rampioni Vinciguerra, Gian Luca, et al.
Publicado: (2022)

CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
por: Ott, Patrick A., et al.
Publicado: (2015)

Editorial: Targeting metabolism of cancer cells and host to overcome drug resistance: Preclinical and clinical studies
por: Wang, Lishun, et al.
Publicado: (2023)

Editorial: Impact of Cancer Plasticity on Drug Resistance and Treatment in Solid Tumors
por: Cohen, Pascale A., et al.
Publicado: (2020)

Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance
por: Mahfoudhi, Emna, et al.
Publicado: (2022)

Editorial: Preclinical models and emerging technologies to study the effects of the tumor microenvironment on cancer heterogeneity and drug resistance
por: Adriani, Giulia, et al.
Publicado: (2023)

Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma
por: Ke, Yuan, et al.
Publicado: (2022)

Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives
por: Roccuzzo, Gabriele, et al.
Publicado: (2021)

Macromolecular Drug Carriers for Targeted Glioblastoma Therapy: Preclinical Studies, Challenges, and Future Perspectives
por: Raucher, Drazen, et al.
Publicado: (2018)

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
por: Zhang, Jinmeng, et al.
Publicado: (2021)

CDK4/6 inhibitor resistance: A bibliometric analysis
por: Pang, Jiayuecheng, et al.
Publicado: (2022)

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
por: Vikas, Praveen, et al.
Publicado: (2020)

Editorial: Interaction Between Modern Radiotherapy and Novel Drugs in Prostate Cancer: Future Perspectives
por: Detti, Beatrice, et al.
Publicado: (2022)

Combining energy-based focal ablation and immune checkpoint inhibitors: preclinical research and clinical trials
por: Jiang, Minhan, et al.
Publicado: (2023)

Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia
por: Timofeeva, Natalia, et al.
Publicado: (2023)

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
por: George, Mridula A., et al.
Publicado: (2021)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Role of Cytokines and Other Soluble Factors in Tumor Development: Rationale for New Therapeutic Strategies
por: Cavazzoni, Andrea, et al.
Publicado: (2023)

Editorial: Bridging quantitative imaging and artificial intelligence methods in preclinical and clinical oncology
por: Jansen, Jacobus FA., et al.
Publicado: (2023)

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
por: McCartney, Amelia, et al.
Publicado: (2019)

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
por: Mittica, Gloria, et al.
Publicado: (2017)

Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer
por: Laha, Dipranjan, et al.
Publicado: (2022)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

Editorial: Evolving roles of piRNAs in solid tumors
por: Ng, Lui, et al.
Publicado: (2023)

Radiotherapy and Erlotinib Combined: Review of the Preclinical and Clinical Evidence
por: Mehta, Vivek K.
Publicado: (2012)

Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy
por: Elbanna, May, et al.
Publicado: (2021)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives
por: Zambelli, Alberto, et al.
Publicado: (2023)

CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?
por: Schröder, Lisette B. W., et al.
Publicado: (2015)

Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
por: Kobold, Sebastian, et al.
Publicado: (2018)

New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway
por: Alfieri, Roberta, et al.
Publicado: (2017)

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
por: Lee, Cha Len, et al.
Publicado: (2023)

Combining the DNA Repair Inhibitor Dbait With Radiotherapy for the Treatment of High Grade Glioma: Efficacy and Protein Biomarkers of Resistance in Preclinical Models
por: Biau, Julian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0fq0q8u7gso8l7op0qu3s53hdm